Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza vaccine quadrivalent - Seqirus

Next Previous
Drug Profile

Influenza vaccine quadrivalent - Seqirus

Alternative Names: Afluria Quad; AFLURIA QUADRIVALENT; aQIV; CSL QIV; Influenza vaccine quadrivalent - bioCSL; Quadrivalent influenza vaccine - (CSL-QIV); Quadrivalent influenza vaccine - bioCSL; Quadrivalent influenza vaccine - Seqirus; Seqirus QIV; Split virion inactivated quadrivalent influenza vaccine - bioCSL

Latest Information Update: 09 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator bioCSL
  • Developer Seqirus
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 15 Jun 2026 Seqirus completes the phase III trial for Influenza virus infections (Prevention) in Belgium, Bulgaria, Czech Republic, Finland, Georgia, Italy, Lithuania, Netherlands, Philippines, Poland, Romania, Spain, Zimbabwe, Turkey, South Korea, South Africa, Taiwan, Australia and New Zealand NCT- Australia, Belgium, Bulgaria, Czechia, Finland, Georgia, Italy, Serbia and USA (NCT06087640)
  • 23 Oct 2023 Phase-III clinical trials in Influenza virus infections (Prevention) in Zimbabwe, Turkey, South Korea, South Africa (IM) (NCT06087640)
  • 23 Oct 2023 Seqirus initiates a phase III trial for Influenza virus infections (Prevention) in Bulgaria, Czech Republic, Finland, Georgia, Italy, Lithuania, Netherlands, Philippines, Poland, Romania, Spain, Taiwan, Australia and USA (NCT06087640)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top